Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Matthew Gline currently holds 16,736,116 shares of Roivant Sciences Ltd. (ROIV), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Matthew Gline has been a net seller of ROIV stock. They have purchased $50.0K and sold $71.8M worth of shares.
Matthew Gline's most recent insider trade was on Apr 16, 2026, when they sold 289,774 shares at $29.16 per share.
Matthew Gline serves as Executive at Roivant Sciences Ltd. (ROIV). They have executed 69 insider transactions totaling $71.8M over their tenure at the company.
Matthew Gline holds the position of Executive at Roivant Sciences Ltd., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 4 years and currently hold a stake valued at $0.
Matthew Gline has shown a selling trading pattern, with $50.0K in total purchases and $71.8M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Matthew Gline was on Dec 15, 2025, when they sold $28.8M worth of ROIV shares. This transaction involved 1,329,325 shares at $21.68 per share.
Matthew Gline currently owns 16,736,116 shares of Roivant Sciences Ltd. (ROIV), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Matthew Gline's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Matthew Gline has 69 Form 4 filings on record as an insider at Roivant Sciences Ltd..
Set alerts for Matthew Gline and 40,000+ other insiders.